A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

The Mediterranean diet has tons of benefits. Find out why the Mediterranean diet may be especially good as you age.

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

States that do provide coverage have tried to manage costs by putting prescribing limits on the GLP-1s. There's also some ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

It seems like everyone and their sister is taking a GLP-1 (“glucagon-like peptide-1 receptor agonists,” if you’re feeling ...

over 6000 assets (including all Forex pairs, Cryptocurrencies, Commodities, Indices and US stocks) unique interbank rates extensive historic data the option to save your configuration Here below ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges. Find out who is the winner.

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.